FATE: fatetherapeutics.com Narx-foyda va o‘sish multiplikatori
Fate Therapeutics, Inc. (FATE) hujayralar xavfsizligi FDA tomonidan qat'iy tartibga solinadigan ilg'or iPSC terapiya tizimini ishlab chiqmoqda. Kompaniya ommaviy ishlab chiqarish uchun universal onkologik dori vositalarining arxitekturasini loyihalashtirmoqda. PEG koeffitsiyenti baholash dinamikasini aks ettiradi, bunda 0.00 qiymati joriy ko'rsatkich vazifasini o'taydi. Sog'liqni saqlash gigantlari bilan strategik ittifoqlar, ushbu grafikda ko'rsatilganidek, ilmiy sinergiyani ta'minlaydi.
Fate Therapeutics, Inc. (FATE) kompaniyasining tahliliy kesimlari
- aksiya narxi va baholash bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- xususiy kapitalning balans qiymati ko'rsatkichlari:
- biznesning qarz tarkibi va likvidligi tafsilotlari:
Qarzning kapitalga nisbati Fate Therapeutics, Inc.|FATE - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning o'z kapitaliga nisbati fatetherapeutics.com|FATE - Kompaniyaning jamlangan qarzlari|Balans kapitallashuviga qarzlar Fate Therapeutics Corp|FATE - Kompaniyaning uzoq muddatli majburiyatlari|Qisqa muddatli majburiyatlar miqdori Fate Therapeutics|Shoshilinch likvidlik fatetherapeutics.com
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
FATE - Sof daromad|Kutilayotgan sof daromad Fate Therapeutics, Inc.|FATE - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning kelajakdagi foydaga nisbati Fate Pharma|FATE - PEG multiplikatori|Biznes qiymatining amortizatsiya chegirilishidan oldingi operatsion foydaga nisbati Fate Therapeutics Corp|FATE - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Fate Therapeutics|FATE - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi fatetherapeutics.com|FATE - Joriy yilda foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Fate Therapeutics, Inc.
Kompaniyaning umumiy tahlili:FATE Fate Therapeutics Inc
PEG koeffitsiyenti joriy P/E ko'paytirgichini foyda kengayishi sur'ati bilan solishtiradi, bu esa aktivning adolatli qiymatini uning o'sish dinamikasiga nisbatan aniqlash imkonini beradi. Ushbu P/E-o'sish grafigini tahlil qilish orqali investor biznesning past baholanganligini aniqlashi mumkin, bu esa Fate Therapeutics, Inc. (FATE) uchun klinik sinovlar davrida va onkologik terapiya bozorini egallash uchun iPSC texnologiyalarini kengaytirish jarayonida juda muhimdir.
Fate Therapeutics, Inc. kimlar bilan raqobatlashadi
ONC (BeiGene Ltd.) - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PEG multiplikatori HALO (Halozyme Inc.)|RVMD - Narx-foyda va o‘sish multiplikatori|AAPG: Narx-foyda va o‘sish multiplikatori|CGON - PEG multiplikatori|UroGen Pharma (URGN) - Narxning foydaga va o‘sish sur’atiga nisbati|Bicara Therapeutics Inc - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|PSNL (Personalis Corp) - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda Erasca Oncology ERAS|PEG multiplikatori DCTH|YMAB: Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati|PEG multiplikatori AURA (Aura Biosciences)|PEG multiplikatori Candel Therapeutics Inc. CADL|ARAY: Narx-foyda va o‘sish multiplikatori|SELLAS Life Sciences - Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|ACTU: PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda citiusonc.com (CTOR)|Narx-foyda va o‘sish multiplikatori HURA|TARA: O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|Narx-foyda va o‘sish multiplikatori WHWK (Aadi Bioscience Inc)|Kompaniya qiymatining foyda o‘sish sur’atiga nisbati TCRX|PEG multiplikatori CSBR (Champions Oncology, Inc.)|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti XBIT|CEL-SCI Corp - PEG multiplikatori|O‘sish sur’atiga tuzatilgan narx-foyda OS Therapies Inc.|Radiopharm Theranostics Limited (RADX) - Narxning foydaga va o‘sish sur’atiga nisbati|Artiva Biotherapeutics - O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti|ANL (Adlai Nortye Ltd) - PEG multiplikatori|PEG multiplikatori verupharma.com|Narxning foydaga va o‘sish sur’atiga nisbati Tempest Therapeutics, Inc. (TPST)|XLO: Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati|PEG multiplikatori RENB (Renovaro)|Mural Oncology PLC (MURA) - O‘sish sur’atiga tuzatilgan narx-foyda|KAPA: Narx-foyda va o‘sish multiplikatori|OKUR - PEG multiplikatori|GDTC (w2.cytomed.sg) - Narx-foyda va o‘sish multiplikatori|CRIS: Kompaniya qiymatining foyda o‘sish sur’atiga nisbati|APLM (Apollomics Inc.) - PEG multiplikatori|Tharimmune Corporation (THAR) - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|PEG multiplikatori ADVB|Narx-foyda va o‘sish multiplikatori genprex.com GNPX|Narxning foydaga va o‘sish sur’atiga nisbati Calidi Biotherapeutics, Inc. CLDI|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati Sunshine Biopharma Inc. (SBFM)|XBIO: Narx-foyda va o‘sish multiplikatori|O‘sish sur’atini hisobga olgan qoplash koeffitsiyenti SLRX (Salarius Pharma)|PPBT: PEG multiplikatori|AONC - O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga va o‘sish sur’atiga nisbati BeiGene|O‘sishni hisobga olgan narx-foyda koeffitsiyenti CKPT (Checkpoint Therapeutics Inc.)|PEG multiplikatori ELEV|Narx-foyda va o‘sish multiplikatori icadmed.com ICAD|Ikena Oncology - Narx-foyda va o‘sish multiplikatori|O‘sish sur’atini hisobga olgan kapitalizatsiyaning sof foydaga nisbati notablelabs.com (NTBL)|Viracta - PEG multiplikatori|Kapitalizatsiyaning foyda va o‘sish sur’atiga nisbati MOR|NAYA: PEG multiplikatori|Ascentage (AAPGV) - PEG multiplikatori
